Growth factors and their receptors in cancer metastases

Frontiers in Bioscience

Volumn 16, Issue 2, 2011, Pages 531-538

  Yang, Shi Yu ^a   Miah, Anur ^a   Pabari, Amit ^a   Winslet, Marc ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Angiogenin; Angiopoietins; EGF; Epithelial mesenchymal transition; FGF; HGF; HIF; IGFs; IL 8; Interleukin 8; Metastases; Review; SMADs; Snail; TGF ; Tissue Factor; TNF ; VEGF

Indexed keywords

GASTROPODA;

ANGIOGENIN; ANGIOPOIETIN; AUTOCRINE MOTILITY FACTOR; ENPP2 PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCOSE 6 PHOSPHATE ISOMERASE; GROWTH FACTOR RECEPTOR; INORGANIC PYROPHOSPHATASE; INTERLEUKIN 8; MULTIENZYME COMPLEX; PANCREATIC RIBONUCLEASE; PHOSPHODIESTERASE I; SCATTER FACTOR; SIGNAL PEPTIDE; SMAD PROTEIN; SNAIL FAMILY TRANSCRIPTION FACTORS; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; APOPTOSIS; CANCER INVASION; CELL MOTION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; TUMOR EMBOLISM; TUMOR SEEDING;

ANGIOPOIETINS; ANIMALS; APOPTOSIS; AUTOCRINE MOTILITY FACTOR; CELL MOVEMENT; EPIDERMAL GROWTH FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; GLUCOSE-6-PHOSPHATE ISOMERASE; HEPATOCYTE GROWTH FACTOR; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-8; MULTIENZYME COMPLEXES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM SEEDING; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHODIESTERASE I; PYROPHOSPHATASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; RECEPTORS, GROWTH FACTOR; RIBONUCLEASE, PANCREATIC; SMAD PROTEINS; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955002379     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3703     Document Type: Article

References (181)

1. B. Weigelt, J. L. Peterse and '. van, V: Breast cancer metastasis: markers and models. Nat.Rev.Cancer, 5(8), 591-602 (2005) (Pubitemid 41081385)
2. W. G. Jiang, M. C. Puntis and M. B. Hallett: Molecular and cellular basis of cancer invasion and metastasis: implications for treatment. Br.J.Surg., 81(11), 1576-1590 (1994) (Pubitemid 24349926)
3. R. D. Cardiff: Epithelial to Mesenchymal Transition Tumors: Fallacious or Snail's Pace? Clin.Cancer Res., 11(24 Pt 1), 8534-8537 (2005) (Pubitemid 43005897)
4. M. Yilmaz and G. Christofori: EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev., 28(1-2), 15-33 (2009)
5. D. A. Lauffenburger and A. F. Horwitz: Cell migration: a physically integrated molecular process. Cell, 84(3), 359-369 (1996) (Pubitemid 26058561)
6. P. Friedl and K. Wolf: Tumour-cell invasion and migration: diversity and escape mechanisms. Nat.Rev.Cancer, 3(5), 362-374 (2003) (Pubitemid 37328856)
7. K. E. Fisher, A. Pop, W. Koh, N. J. Anthis, W. B. Saunders and G. E. Davis: Tumor cell invasion of collagen matrices requires coordinate lipid agonist-induced Gprotein and membrane-type matrix metalloproteinase-1- dependent signaling. Mol.Cancer, 5, 69 (2006)
8. J. B. Wyckoff, J. G. Jones, J. S. Condeelis and J. E. Segall: A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. Cancer Res., 60(9), 2504-2511 (2000) (Pubitemid 30262445)
9. B. Z. Qian and J. W. Pollard: Macrophage diversity enhances tumor progression and metastasis. Cell, 141(1), 39-51 (2010)
10. P. Mehlen and A. Puisieux: Metastasis: a question of life or death. Nat.Rev.Cancer, 6(6), 449-458 (2006)
11. G. V. Glinsky, V. V. Glinsky, A. B. Ivanova and C. J. Hueser: Apoptosis and metastasis: increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. Cancer Lett., 115(2), 185-193 (1997) (Pubitemid 27196604)
12. A. Russo, V. Bazan, B. Iacopetta, D. Kerr, T. Soussi and N. Gebbia: The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J.Clin.Oncol., 23(30), 7518-7528 (2005) (Pubitemid 46291815)
13. S. Y. Yang, K. M. Sales, B. Fuller, A. M. Seifalian and M. C. Winslet: Apoptosis and colorectal cancer: implications for therapy. Trends Mol.Med., 15(5), 225-233 (2009)
14. K. J. Luzzi, I. C. MacDonald, E. E. Schmidt, N. Kerkvliet, V. L. Morris, A. F. Chambers and A. C. Groom: Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am.J.Pathol., 153(3), 865-873 (1998) (Pubitemid 28419039)
15. G. Schackert, J. E. Price, R. D. Zhang, C. D. Bucana, K. Itoh and I. J. Fidler: Regional growth of different human melanomas as metastases in the brain of nude mice. Am.J.Pathol., 136(1), 95-102 (1990) (Pubitemid 20034956)
16. S. Sheng, M. Qiao and A. B. Pardee: Metastasis and AKT activation. J.Cell Physiol, 218(3), 451-454 (2009)
17. J. Folkman: The role of angiogenesis in tumor growth. Semin.Cancer Biol., 3(2), 65-71 (1992)
18. L. Holmgren, M. S. O'Reilly and J. Folkman: Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat.Med., 1(2), 149-153 (1995)
19. J. A. Joyce and J. W. Pollard: Microenvironmental regulation of metastasis. Nat.Rev.Cancer, 9(4), 239-252 (2009)
20. G. L. Nicolson: Cancer progression and growth: relationship of paracrine and autocrine growth mechanisms to organ preference of metastasis. Exp.Cell Res., 204(2), 171-180 (1993) (Pubitemid 23200179)
21. Y. Shi and J. Massague: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell, 113(6), 685-700 (2003) (Pubitemid 36724933)
22. R. Derynck and X. H. Feng: TGF-beta receptor signaling. Biochim.Biophys.Acta, 1333(2), F105-F150 (1997)
23. J. Massague: TGF-beta signal transduction. Annu.Rev.Biochem., 67, 753-791 (1998)
24. S. D. Markowitz and A. B. Roberts: Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev., 7(1), 93-102 (1996) (Pubitemid 27202668)
25. A. B. Roberts and L. M. Wakefield: The two faces of transforming growth factor beta in carcinogenesis. Proc.Natl.Acad.Sci.U.S.A, 100(15), 8621-8623 (2003) (Pubitemid 36899145)
26. J. P. Thiery and J. P. Sleeman: Complex networks orchestrate epithelial-mesenchymal transitions. Nat.Rev.Mol.Cell Biol., 7(2), 131-142 (2006) (Pubitemid 43278296)
27. J. Zavadil and E. P. Bottinger: TGF-beta and epithelialto- mesenchymal transitions. Oncogene, 24(37), 5764-5774 (2005)
28. M. Oft, J. Peli, C. Rudaz, H. Schwarz, H. Beug and E. Reichmann: TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev., 10(19), 2462-2477 (1996) (Pubitemid 26341881)
29. J. Massague and R. R. Gomis: The logic of TGFbeta signaling. FEBS Lett., 580(12), 2811-2820 (2006)
30. N. A. Wahab and R. M. Mason: A critical look at growth factors and epithelial-to-mesenchymal transition in the adult kidney. Interrelationships between growth factors that regulate EMT in the adult kidney. Nephron Exp.Nephrol., 104(4), e129-e134 (2006) (Pubitemid 44885059)
31. P. Papageorgis, A. W. Lambert, S. Ozturk, F. Gao, H. Pan, U. Manne, Y. O. Alekseyev, A. Thiagalingam, H. M. Abdolmaleky, M. Lenburg and S. Thiagalingam: Smad signaling is required to maintain epigenetic silencing during breast cancer progression. Cancer Res., 70(3), 968-978 (2010)
32. T. Ebisawa, M. Fukuchi, G. Murakami, T. Chiba, K. Tanaka, T. Imamura and K. Miyazono: Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J.Biol.Chem., 276(16), 12477-12480 (2001)
33. L. Ulloa, J. Doody and J. Massague: Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature, 397(6721), 710-713 (1999)
34. Y. Wu and B. P. Zhou: TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br.J.Cancer, 102(4), 639-644 (2010)
35. T. A. Martin, A. Goyal, G. Watkins and W. G. Jiang: Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann.Surg.Oncol., 12(6), 488-496 (2005) (Pubitemid 40884264)
36. H. Peinado, D. Olmeda and A. Cano: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat.Rev.Cancer, 7(6), 415-428 (2007) (Pubitemid 46809165)
37. Y. Wu, J. Deng, P. G. Rychahou, S. Qiu, B. M. Evers and B. P. Zhou: Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell, 15(5), 416-428 (2009)
38. L. A. Liotta, R. Mandler, G. Murano, D. A. Katz, R. K. Gordon, P. K. Chiang and E. Schiffmann: Tumor cell autocrine motility factor. Proc.Natl.Acad.Sci.U.S.A, 83(10), 3302-3306 (1986) (Pubitemid 16043024)
39. H. Watanabe, K. Takehana, M. Date, T. Shinozaki and A. Raz: Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide. Cancer Res., 56(13), 2960-2963 (1996) (Pubitemid 26199739)
40. M. Fairbank, P. St-Pierre and I. R. Nabi: The complex biology of autocrine motility factor/phosphoglucose isomerase (AMF/PGI) and its receptor, the gp78/AMFR E3 ubiquitin ligase. Mol.Biosyst., 5(8), 793-801 (2009)
41. S. Tsutsumi, T. Yanagawa, T. Shimura, T. Fukumori, V. Hogan, H. Kuwano and A. Raz: Regulation of cell proliferation by autocrine motility factor/phosphoglucose isomerase signaling. J.Biol.Chem., 278(34), 32165-32172 (2003) (Pubitemid 37048407)
42. S. Tsutsumi, V. Hogan, I. R. Nabi and A. Raz: Overexpression of the autocrine motility factor/phosphoglucose isomerase induces transformation and survival of NIH-3T3 fibroblasts. Cancer Res., 63(1), 242-249 (2003) (Pubitemid 36070446)
43. S. Tsutsumi, S. K. Gupta, V. Hogan, N. Tanaka, K. T. Nakamura, I. R. Nabi and A. Raz: The enzymatic activity of phosphoglucose isomerase is not required for its cytokine function. FEBS Lett., 534(1-3), 49-53 (2003) (Pubitemid 36084517)
44. M. L. Stracke, H. C. Krutzsch, E. J. Unsworth, A. Arestad, V. Cioce, E. Schiffmann and L. A. Liotta: Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J.Biol.Chem., 267(4), 2524-2529 (1992)
45. M. J. Stassar, G. Devitt, M. Brosius, L. Rinnab, J. Prang, T. Schradin, J. Simon, S. Petersen, A. Kopp-Schneider and M. Zoller: Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. Br.J.Cancer, 85(9), 1372-1382 (2001) (Pubitemid 33081935)
46. M. L. Stracke, T. Clair and L. A. Liotta: Autotaxin, tumor motility-stimulating exophosphodiesterase. Adv.Enzyme Regul., 37, 135-144 (1997) (Pubitemid 27371559)
47. S. W. Nam, T. Clair, C. K. Campo, H. Y. Lee, L. A. Liotta and M. L. Stracke: Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene, 19(2), 241-247 (2000) (Pubitemid 30077220)
48. D. B. Hoelzinger, L. Mariani, J. Weis, T. Woyke, T. J. Berens, W. S. McDonough, A. Sloan, S. W. Coons and M. E. Berens: Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia., 7(1), 7-16 (2005) (Pubitemid 40209466)
49. A. Masuda, K. Nakamura, K. Izutsu, K. Igarashi, R. Ohkawa, M. Jona, K. Higashi, H. Yokota, S. Okudaira, T. Kishimoto, T. Watanabe, Y. Koike, H. Ikeda, Y. Kozai, M. Kurokawa, J. Aoki and Y. Yatomi: Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. Br.J.Haematol., 143(1), 60-70 (2008)
50. A. D. Singh, K. Sisley, Y. Xu, J. Li, P. Faber, S. J. Plummer, H. S. Mudhar, I. G. Rennie, P. M. Kessler, G. Casey and B. G. Williams: Reduced expression of autotaxin predicts survival in uveal melanoma. Br.J.Ophthalmol., 91(10), 1385-1392 (2007) (Pubitemid 47492881)
51. K. R. Baumforth, J. R. Flavell, G. M. Reynolds, G. Davies, T. R. Pettit, W. Wei, S. Morgan, T. Stankovic, Y. Kishi, H. Arai, M. Nowakova, G. Pratt, J. Aoki, M. J. Wakelam, L. S. Young and P. G. Murray: Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. Blood, 106(6), 2138-2146 (2005) (Pubitemid 41291731)
52. J. A. Boutin and G. Ferry: Autotaxin. Cell Mol.Life Sci., 66(18), 3009-3021 (2009)
53. J. Murata, H. Y. Lee, T. Clair, H. C. Krutzsch, A. A. Arestad, M. E. Sobel, L. A. Liotta and M. L. Stracke: cDNA cloning of the human tumor motility-stimulating protein, autotaxin, reveals a homology with phosphodiesterases. J.Biol.Chem., 269(48), 30479-30484 (1994) (Pubitemid 24376528)
54. Z. Lu, G. Jiang, P. Blume-Jensen and T. Hunter: Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol.Cell Biol., 21(12), 4016-4031 (2001) (Pubitemid 32476463)
55. D. S. Salomon, R. Brandt, F. Ciardiello and N. Normanno: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev.Oncol.Hematol., 19(3), 183-232 (1995)
56. J. M. Ricono, M. Huang, L. A. Barnes, S. K. Lau, S. M. Weis, D. D. Schlaepfer, S. K. Hanks and D. A. Cheresh: Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res., 69(4), 1383-1391 (2009)
57. T. Takahashi, N. Yamamoto, T. Nukiwa, K. Mori, M. Tsuboi, T. Horai, N. Masuda, K. Eguchi, T. Mitsudomi, S. Yokota, Y. Segawa, Y. Ichinose, M. Fukuoka and N. Saijo: Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer. Anticancer Res., 30(2), 557-563 (2010)
58. J. M. Summy and G. E. Gallick: Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev., 22(4), 337-358 (2003) (Pubitemid 36791891)
59. T. Nakamura, T. Nishizawa, M. Hagiya, T. Seki, M. Shimonishi, A. Sugimura, K. Tashiro and S. Shimizu: Molecular cloning and expression of human hepatocyte growth factor. Nature, 342(6248), 440-443 (1989) (Pubitemid 19277521)
60. M. Stoker and E. Gherardi: Regulation of cell movement: the motogenic cytokines. Biochim.Biophys.Acta, 1072(1), 81-102 (1991) (Pubitemid 121007531)
61. J. Yamashita, M. Ogawa, S. Yamashita, K. Nomura, M. Kuramoto, T. Saishoji and S. Shin: Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res., 54(7), 1630-1633 (1994) (Pubitemid 24116158)
62. M. F. Di Renzo, M. Olivero, A. Giacomini, H. Porte, E. Chastre, L. Mirossay, B. Nordlinger, S. Bretti, S. Bottardi, S. Giordano and.: Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin.Cancer Res., 1(2), 147-154 (1995)
63. W. G. Jiang, S. Hiscox, M. B. Hallett, C. Scott, D. F. Horrobin and M. C. Puntis: Inhibition of hepatocyte growth factor-induced motility and in vitro invasion of human colon cancer cells by gamma-linolenic acid. Br.J.Cancer, 71(4), 744-752 (1995)
64. W. G. Jiang, S. Hiscox, S. K. Singhrao, T. Nakamura, M. C. Puntis and M. B. Hallett: Inhibition of HGF/Sfinduced membrane ruffling and cell motility by transient elevation of cytosolic free Ca2+. Exp.Cell Res., 220(2), 424-433 (1995)
65. W. G. Jiang, S. Hiscox, S. K. Singhrao, M. C. Puntis, T. Nakamura, R. E. Mansel and M. B. Hallett: Induction of tyrosine phosphorylation and translocation of ezrin by hepatocyte growth factor/scatter factor. Biochem.Biophys.Res.Commun., 217(3), 1062-1069 (1995) (Pubitemid 26019760)
66. K. Reisinger, R. Kaufmann and J. Gille: Increased Sp1 phosphorylation as a mechanism of hepatocyte growth factor (HGF/SF)-induced vascular endothelial growth factor (VEGF/VPF) transcription. J.Cell Sci., 116(Pt 2), 225-238 (2003) (Pubitemid 36163864)
67. L. Tacchini, P. Dansi, E. Matteucci and M. A. Desiderio: Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells. Carcinogenesis, 22(9), 1363-1371 (2001) (Pubitemid 32898691)
68. W. G. Jiang, T. A. Martin, C. Parr, G. Davies, K. Matsumoto and T. Nakamura: Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev.Oncol.Hematol., 53(1), 35-69 (2005) (Pubitemid 39656109)
69. R. Zhou, D. Diehl, A. Hoeflich, H. Lahm and E. Wolf: IGFbinding protein-4: biochemical characteristics and functional consequences. J.Endocrinol., 178(2), 177-193 (2003) (Pubitemid 37063060)
70. S. Rajaram, D. J. Baylink and S. Mohan: Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr.Rev., 18(6), 801-831 (1997) (Pubitemid 28009568)
71. A. Grimberg and P. Cohen: Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J.Cell Physiol, 183(1), 1-9 (2000) (Pubitemid 30130219)
72. S. L. Leng, K. S. Leeding, R. H. Whitehead and L. A. Bach: Insulin-like growth factor (IGF)-binding protein-6 inhibits IGF-II-induced but not basal proliferation and adhesion of LIM 1215 colon cancer cells. Mol.Cell Endocrinol., 174(1-2), 121-127 (2001) (Pubitemid 32288875)
73. S. J. Moschos and C. S. Mantzoros: The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology, 63(4), 317-332 (2002) (Pubitemid 36151524)
74. F. Andre, B. Janssens, E. Bruyneel, R. F. van, C. Gespach, M. Mareel and M. Bracke: Alpha-catenin is required for IGF-Iinduced cellular migration but not invasion in human colonic cancer cells. Oncogene, 23(6), 1177-1186 (2004) (Pubitemid 38297171)
75. T. W. Bauer, F. Fan, W. Liu, M. Johnson, N. U. Parikh, G. C. Parry, J. Callahan, A. P. Mazar, G. E. Gallick and L. M. Ellis: Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor. Ann.Surg., 241(5), 748-756 (2005)
76. Y. Wu, S. Yakar, L. Zhao, L. Hennighausen and D. LeRoith: Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res., 62(4), 1030-1035 (2002) (Pubitemid 34160283)
77. T. Oshima, M. Akaike, K. Yoshihara, M. Shiozawa, N. Yamamoto, T. Sato, R. Yamada, S. Fujii, Y. Rino, C. Kunisaki, K. Tanaka, M. Masuda and T. Imada: Clinicopathological significance of the gene expression of matrix metalloproteinase-7, insulin-like growth factor-1, insulin-like growth factor-2 and insulin-like growth factor- 1 receptor in patients with colorectal cancer: insulin-like growth factor-1 receptor gene expression is a useful predictor of liver metastasis from colorectal cancer. Oncol.Rep., 20(2), 359-364 (2008)
78. S. Miyamoto, M. Nakamura, K. Shitara, K. Nakamura, Y. Ohki, G. Ishii, M. Goya, K. Kodama, T. Sangai, H. Maeda, Z. Shi-Chuang, T. Chiba and A. Ochiai: Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers. Clin.Cancer Res., 11(9), 3494-3502 (2005) (Pubitemid 40627904)
79. A. Canonici, W. Steelant, V. Rigot, A. Khomitch-Baud, H. Boutaghou-Cherid, E. Bruyneel, R. F. van, F. Garrouste, G. Pommier and F. Andre: Insulin-like growth factor-I receptor, E-cadherin and alpha v integrin form a dynamic complex under the control of alpha-catenin. Int.J.Cancer, 122(3), 572-582 (2008) (Pubitemid 350308948)
80. B. B. Aggarwal, S. Shishodia, K. Ashikawa and A. C. Bharti: The role of TNF and its family members in inflammation and cancer: lessons from gene deletion. Curr.Drug Targets.Inflamm.Allergy, 1(4), 327-341 (2002)
81. P. Orosz, B. Echtenacher, W. Falk, J. Ruschoff, D. Weber and D. N. Mannel: Enhancement of experimental metastasis by tumor necrosis factor. J.Exp.Med., 177(5), 1391-1398 (1993) (Pubitemid 23117129)
82. M. Liang, P. Zhang and J. Fu: Up-regulation of LOX-1 expression by TNF-alpha promotes trans-endothelial migration of MDA-MB-231 breast cancer cells. Cancer Lett., 258(1), 31-37 (2007) (Pubitemid 47600486)
83. R. Montesano, P. Soulie, J. A. Eble and F. Carrozzino: Tumour necrosis factor alpha confers an invasive, transformed phenotype on mammary epithelial cells. J.Cell Sci., 118(Pt 15), 3487-3500 (2005) (Pubitemid 41246102)
84. H. L. Chua, P. Bhat-Nakshatri, S. E. Clare, A. Morimiya, S. Badve and H. Nakshatri: NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene, 26(5), 711-724 (2007) (Pubitemid 46204250)
85. M. J. Chuang, K. H. Sun, S. J. Tang, M. W. Deng, Y. H. Wu, J. S. Sung, T. L. Cha and G. H. Sun: Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Sci., 99(5), 905-913 (2008)
86. K. Garber: First results for agents targeting cancer-related inflammation. J.Natl.Cancer Inst., 101(16), 1110-1112 (2009)
87. P. W. Szlosarek and F. R. Balkwill: Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol., 4(9), 565-573 (2003) (Pubitemid 38351714)
88. D. Sachdev, J. S. Hartell, A. V. Lee, X. Zhang and D. Yee: A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J.Biol.Chem., 279(6), 5017-5024 (2004) (Pubitemid 38199098)
89. D. Sachdev, X. Zhang, I. Matise, M. Gaillard-Kelly and D. Yee: The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene, 29(2), 251-262 (2010)
90. S. Y. Yang, K. M. Sales, B. J. Fuller, A. M. Seifalian and M. C. Winslet: Inducing apoptosis of human colon cancer cells by an IGF-I D domain analogue peptide. Mol.Cancer, 7, 17 (2008)
91. J. H. Im, W. Fu, H. Wang, S. K. Bhatia, D. A. Hammer, M. A. Kowalska and R. J. Muschel: Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res., 64(23), 8613-8619 (2004) (Pubitemid 39552074)
92. J. S. Palumbo: Mechanisms linking tumor cellassociated procoagulant function to tumor dissemination. Semin.Thromb.Hemost., 34(2), 154-160 (2008)
93. G. F. Nash, L. F. Turner, M. F. Scully and A. K. Kakkar: Platelets and cancer. Lancet Oncol., 3(7), 425-430 (2002) (Pubitemid 36958273)
94. E. F. Wheelock, K. J. Weinhold and J. Levich: The tumor dormant state. Adv.Cancer Res., 34, 107-140 (1981)
95. M. C. Brahimi-Horn, J. Chiche and J. Pouyssegur: Hypoxia and cancer. J.Mol.Med., 85(12), 1301-1307 (2007) (Pubitemid 50004093)
96. J. Chiche, K. Ilc, J. Laferriere, E. Trottier, F. Dayan, N. M. Mazure, M. C. Brahimi-Horn and J. Pouyssegur: Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res., 69(1), 358-368 (2009)
97. G. Bellot, R. Garcia-Medina, P. Gounon, J. Chiche, D. Roux, J. Pouyssegur and N. M. Mazure: Hypoxiainduced autophagy is mediated through hypoxiainducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol.Cell Biol., 29(10), 2570-2581 (2009)
98. J. T. Erler, K. L. Bennewith, M. Nicolau, N. Dornhofer, C. Kong, Q. T. Le, J. T. Chi, S. S. Jeffrey and A. J. Giaccia: Lysyl oxidase is essential for hypoxiainduced metastasis. Nature, 440(7088), 1222-1226 (2006)
99. G. Melillo: Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev., 26(2), 341-352 (2007) (Pubitemid 47101663)
100. D. W. Leung, G. Cachianes, W. J. Kuang, D. V. Goeddel and N. Ferrara: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 246(4935), 1306-1309 (1989) (Pubitemid 20066716)
101. Y. Takahashi, Y. Kitadai, C. D. Bucana, K. R. Cleary and L. M. Ellis: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res., 55(18), 3964-3968 (1995)
102. M. Relf, S. LeJeune, P. A. Scott, S. Fox, K. Smith, R. Leek, A. Moghaddam, R. Whitehouse, R. Bicknell and A. L. Harris: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res., 57(5), 963-969 (1997) (Pubitemid 27098025)
103. C. Margaritescu, D. Pirici, C. Simionescu, L. Mogoanta, M. Raica, A. Stinga, R. Ciurea, A. Stepan, A. Stinga and D. Ribatti: VEGF and VEGFRs expression in oral squamous cell carcinoma. Rom.J.Morphol.Embryol., 50(4), 527-548 (2009)
104. N. Ferrara, H. P. Gerber and J. LeCouter: The biology of VEGF and its receptors. Nat.Med., 9(6), 669-676 (2003) (Pubitemid 36749215)
105. L. E. Benjamin, D. Golijanin, A. Itin, D. Pode and E. Keshet: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J.Clin.Invest, 103(2), 159-165 (1999) (Pubitemid 29053133)
106. H. F. Dvorak: Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J.Clin.Oncol., 20(21), 4368-4380 (2002) (Pubitemid 35266299)
107. N. Itoh and D. M. Ornitz: Evolution of the Fgf and Fgfr gene families. Trends Genet., 20(11), 563-569 (2004) (Pubitemid 39314564)
108. R. Khurana and M. Simons: Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease. Trends Cardiovasc.Med., 13(3), 116-122 (2003) (Pubitemid 36411807)
109. T. M. Katona, B. L. Neubauer, P. W. Iversen, S. Zhang, L. A. Baldridge and L. Cheng: Elevated expression of angiogenin in prostate cancer and its precursors. Clin.Cancer Res., 11(23), 8358-8363 (2005) (Pubitemid 41746948)
110. L. Campo, H. Turley, C. Han, F. Pezzella, K. C. Gatter, A. L. Harris and S. B. Fox: Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival. J.Pathol., 205(5), 585-591 (2005) (Pubitemid 40514831)
111. T. Etoh, K. Shibuta, G. F. Barnard, S. Kitano and M. Mori: Angiogenin expression in human colorectal cancer: the role of focal macrophage infiltration. Clin.Cancer Res., 6(9), 3545-3551 (2000)
112. P. Vihinen, M. Kallioinen, M. S. Vuoristo, J. Ivaska, K. J. Syrjanen, M. Hahka-Kemppinen, P. L. Kellokumpu- Lehtinen and S. O. Pyrhonen: Serum angiogenin levels predict treatment response in patients with stage IV melanoma. Clin.Exp.Metastasis, 24(7), 567-574 (2007) (Pubitemid 47524814)
113. F. Soncin, R. Shapiro and J. W. Fett: A cell-surface proteoglycan mediates human adenocarcinoma HT-29 cell adhesion to human angiogenin. J.Biol.Chem., 269(12), 8999-9005 (1994) (Pubitemid 24209218)
114. N. Yoshioka, L. Wang, K. Kishimoto, T. Tsuji and G. F. Hu: A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation. Proc.Natl.Acad.Sci.U.S.A, 103(39), 14519-14524 (2006) (Pubitemid 44484782)
115. X. Gao and Z. Xu: Mechanisms of action of angiogenin. Acta Biochim.Biophys.Sin.(Shanghai), 40(7), 619-624 (2008) (Pubitemid 352009084)
116. J. Heidemann, H. Ogawa, M. B. Dwinell, P. Rafiee, C. Maaser, H. R. Gockel, M. F. Otterson, D. M. Ota, N. Lugering, W. Domschke and D. G. Binion: Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J.Biol.Chem., 278(10), 8508-8515 (2003) (Pubitemid 36800603)
117. M. Haraguchi, K. Komuta, A. Akashi, S. Matsuzaki, J. Furui and T. Kanematsu: Elevated IL-8 levels in the drainage vein of resectable Dukes' C colorectal cancer indicate high risk for developing hepatic metastasis. Oncol.Rep., 9(1), 159-165 (2002)
118. J. E. De Larco, B. R. Wuertz, K. A. Rosner, S. A. Erickson, D. E. Gamache, J. C. Manivel and L. T. Furcht: A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am.J.Pathol., 158(2), 639-646 (2001) (Pubitemid 32158624)
119. W. E. Holmes, J. Lee, W. J. Kuang, G. C. Rice and W. I. Wood: Structure and functional expression of a human interleukin-8 receptor. Science. 1991. 253: 1278-1280. J.Immunol., 183(5), 2895-2897 (2009)
120. C. H. Cho, K. E. Kim, J. Byun, H. S. Jang, D. K. Kim, P. Baluk, F. Baffert, G. M. Lee, N. Mochizuki, J. Kim, B. H. Jeon, D. M. McDonald and G. Y. Koh: Long-term and sustained COMP-Ang1 induces long-lasting vascular enlargement and enhanced blood flow. Circ.Res., 97(1), 86-94 (2005) (Pubitemid 40982326)
121. P. C. Maisonpierre, C. Suri, P. F. Jones, S. Bartunkova, S. J. Wiegand, C. Radziejewski, D. Compton, J. McClain, T. H. Aldrich, N. Papadopoulos, T. J. Daly, S. Davis, T. N. Sato and G. D. Yancopoulos: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science, 277(5322), 55-60 (1997) (Pubitemid 27450643)
122. G. Thurston: Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res., 314(1), 61-68 (2003) (Pubitemid 37409913)
123. S. Wildi, J. Kleeff, H. Maruyama, C. A. Maurer, M. W. Buchler and M. Korc: Overexpression of activin A in stage IV colorectal cancer. Gut, 49(3), 409-417 (2001) (Pubitemid 32802577)
124. S. Khambata-Ford, C. R. Garrett, N. J. Meropol, M. Basik, C. T. Harbison, S. Wu, T. W. Wong, X. Huang, C. H. Takimoto, A. K. Godwin, B. R. Tan, S. S. Krishnamurthi, H. A. Burris, III, E. A. Poplin, M. Hidalgo, J. Baselga, E. A. Clark and D. J. Mauro: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J.Clin.Oncol., 25(22), 3230-3237 (2007) (Pubitemid 47325606)
125. A. H. Wiese, J. Auer, S. Lassmann, J. Nahrig, R. Rosenberg, H. Hofler, R. Ruger and M. Werner: Identification of gene signatures for invasive colorectal tumor cells. Cancer Detect.Prev., 31(4), 282-295 (2007) (Pubitemid 47562633)
126. U. M. Wikesjo, M. Qahash, R. C. Thomson, A. D. Cook, M. D. Rohrer, J. M. Wozney and W. R. Hardwick: rhBMP-2 significantly enhances guided bone regeneration. Clin.Oral Implants.Res., 15(2), 194-204 (2004) (Pubitemid 40109804)
127. K. Loh, J. A. Chia, S. Greco, S. J. Cozzi, R. L. Buttenshaw, C. E. Bond, L. A. Simms, T. Pike, J. P. Young, J. R. Jass, K. J. Spring, B. A. Leggett and V. L. Whitehall: Bone morphogenic protein 3 inactivation is an early and frequent event in colorectal cancer development. Genes Chromosomes.Cancer, 47(6), 449-460 (2008) (Pubitemid 351657180)
128. H. Deng, R. Makizumi, T. S. Ravikumar, H. Dong, W. Yang and W. L. Yang: Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp.Cell Res., 313(5), 1033-1044 (2007) (Pubitemid 46273448)
129. C. Grijelmo, C. Rodrigue, M. Svrcek, E. Bruyneel, A. Hendrix, W. O. de and C. Gespach: Proinvasive activity of BMP-7 through SMAD4/src-independent and ERK/Rac/JNK-dependent signaling pathways in colon cancer cells. Cell Signal., 19(8), 1722-1732 (2007) (Pubitemid 46935428)
130. U. Demirci, U. Coskun, B. Sancak, B. Ozturk, B. Bahar, M. Benekli and S. Buyukberber: Serum granulocyte macrophage-colony stimulating factor: a tumor marker in colorectal carcinoma? Asian Pac.J.Cancer Prev., 10(6), 1021-1024 (2009)
131. M. Trutmann, L. Terracciano, C. Noppen, J. Kloth, M. Kaspar, R. Peterli, P. Tondelli, C. Schaeffer, P. Zajac, M. Heberer and G. C. Spagnoli: GM-CSF gene expression and protein production in human colorectal cancer cell lines and clinical tumor specimens. Int.J.Cancer, 77(3), 378-385 (1998) (Pubitemid 28299873)
132. H. Takahashi, A. Yasuda, N. Ochi, M. Sakamoto, S. Takayama, T. Wakasugi, H. Funahashi, H. Sawai, M. Satoh, Y. Akamo and H. Takeyama: Granulocyte-colony stimulating factor producing rectal cancer. World J.Surg.Oncol., 6, 70 (2008)
133. B. Mroczko, M. Groblewska, U. Wereszczynska- Siemiatkowska, B. Okulczyk, B. Kedra, W. Laszewicz, A. Dabrowski and M. Szmitkowski: Serum macrophagecolony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clin.Chim.Acta, 380(1-2), 208-212 (2007) (Pubitemid 46498063)
134. R. Kopp, E. Rothbauer, M. Ruge, H. Arnholdt, J. Spranger, M. Muders, D. G. Pfeiffer, F. W. Schildberg and A. Pfeiffer: Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. Recent Results Cancer Res., 162, 115-132 (2003)
135. B. Jacobs, R. W. De, H. Piessevaux, O. R. Van, B. Biesmans, S. J. De, S. Fieuws, J. Vandesompele, M. Peeters, J. L. Van Laethem, Y. Humblet, F. Penault-Llorca, H. G. De, P. Laurent-Puig, C. E. Van and S. Tejpar: Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J.Clin.Oncol., 27(30), 5068-5074 (2009)
136. S. Khambata-Ford, C. R. Garrett, N. J. Meropol, M. Basik, C. T. Harbison, S. Wu, T. W. Wong, X. Huang, C. H. Takimoto, A. K. Godwin, B. R. Tan, S. S. Krishnamurthi, H. A. Burris, III, E. A. Poplin, M. Hidalgo, J. Baselga, E. A. Clark and D. J. Mauro: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J.Clin.Oncol., 25(22), 3230-3237 (2007) (Pubitemid 47325606)
137. T. Sato, S. Kusaka, H. Shimojo and T. Fujikado: Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. Ophthalmology, 116(11), 2165-2169 (2009)
138. E. Sundlisaeter, G. V. Rosland, J. K. Hertel, P. O. Sakariassen, B. Almas, A. Dicko and K. Sondenaa: Increased lymphatic vascular density is seen before colorectal cancers reach stage II and growth factor FGF-2 is downregulated in tumor tissue compared with normal mucosa. APMIS, 117(3), 212-221 (2009)
139. K. Narita, T. Fujii, T. Ishiwata, T. Yamamoto, Y. Kawamoto, K. Kawahara, N. Nakazawa and Z. Naito: Keratinocyte growth factor induces vascular endothelial growth factor-A expression in colorectal cancer cells. Int.J.Oncol., 34(2), 355-360 (2009)
140. A. Matsuike, T. Ishiwata, M. Watanabe and G. Asano: Expression of fibroblast growth factor (FGF)-10 in human colorectal adenocarcinoma cells. J.Nippon Med.Sch, 68(5), 397-404 (2001)
141. T. Yokoe, T. Ohmachi, H. Inoue, K. Mimori, F. Tanaka, M. Kusunoki and M. Mori: Clinical significance of growth differentiation factor 11 in colorectal
142. A. W. Roddam, N. E. Allen, P. Appleby, T. J. Key, L. Ferrucci, H. B. Carter, E. J. Metter, C. Chen, N. S. Weiss, A. Fitzpatrick, A. W. Hsing, J. V. Lacey, Jr., K. Helzlsouer, S. Rinaldi, E. Riboli, R. Kaaks, J. A. Janssen, M. F. Wildhagen, F. H. Schroder, E. A. Platz, M. Pollak, E. Giovannucci, C. Schaefer, C. P. Quesenberry, Jr., J. H. Vogelman, G. Severi, D. R. English, G. G. Giles, P. Stattin, G. Hallmans, M. Johansson, J. M. Chan, P. Gann, S. E. Oliver, J. M. Holly, J. Donovan, F. Meyer, I. Bairati and P. Galan: Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann.Intern.Med., 149(7), 461-468 (2008)
143. K. Kawamoto, H. Onodera, S. Kondo, S. Kan, D. Ikeuchi, S. Maetani and M. Imamura: Expression of insulin-like growth factor-2 can predict the prognosis of human colorectal cancer patients: correlation with tumor progression, proliferative activity and survival. Oncology, 55(3), 242-248 (1998) (Pubitemid 28154513)
144. C. Grande, J. L. Firvida, V. Navas and J. Casal: Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma. Anticancer Drugs, 17(1), 1-12 (2006)
145. B. Mroczko, M. Szmitkowski and B. Okulczyk: Hematopoietic growth factors in colorectal cancer patients. Clin.Chem.Lab Med., 41(5), 646-651 (2003) (Pubitemid 36722819)
146. B. H. Li, X. Z. Yang, P. D. Li, Q. Yuan, X. H. Liu, J. Yuan and W. J. Zhang: IL-4/Stat6 activities correlate with apoptosis and metastasis in colon cancer cells. Biochem.Biophys.Res.Commun., 369(2), 554-560 (2008)
147. I. Contasta, A. M. Berghella, P. Pellegrini and D. Adorno: Passage from normal mucosa to adenoma and colon cancer: alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functions. Cancer Biother.Radiopharm., 18(4), 549-557 (2003) (Pubitemid 37082374)
148. H. Knupfer and R. Preiss: Serum interleukin-6 levels in colorectal cancer patients-a summary of published results. Int.J.Colorectal Dis., 25(2), 135-140 (2010)
149. A. M. Berghella, I. Contasta, P. Pellegrini, B. T. Del and D. Adorno: Peripheral blood immunological parameters for use as markers of pre-invasive to invasive colorectal cancer. Cancer Biother.Radiopharm., 17(1), 43-50 (2002) (Pubitemid 34211014)
150. C. Rubie, V. O. Frick, S. Pfeil, M. Wagner, O. Kollmar, B. Kopp, S. Graber, B. M. Rau and M. K. Schilling: Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer. World J.Gastroenterol., 13(37), 4996-5002 (2007) (Pubitemid 47496833)
151. A. M. Berghella, P. Pellegrini, B. T. Del, D. Adorno and C. U. Casciani: IL-10 and sIL-2R serum levels as possible peripheral blood prognostic markers in the passage from adenoma to colorectal cancer. Cancer Biother.Radiopharm., 12(4), 265-272 (1997) (Pubitemid 28030195)
152. V. O. Lewis, M. G. Ozawa, M. T. Deavers, G. Wang, T. Shintani, W. Arap and R. Pasqualini: The interleukin-11 receptor alpha as a candidate ligand-directed target in osteosarcoma: consistent data from cell lines, orthotopic models, and human tumor samples. Cancer Res., 69(5), 1995-1999 (2009)
153. Y. Nakayama, T. Sako, K. Shibao, K. Onitsuka, N. Nagashima, K. Hirata, N. Nagata and H. Itoh: Relationship between plasma levels of vascular endothelial growth factor and serum levels of interleukin-12 in patients with colorectal cancer. Anticancer Res., 20(6A), 4097-4102 (2000)
154. P. Mandal, M. T. Pritchard and L. E. Nagy: Antiinflammatory pathways and alcoholic liver disease: role of an adiponectin/interleukin-10/heme oxygenase-1 pathway. World J.Gastroenterol., 16(11), 1330-1336 (2010)
155. G. Malamut, M. R. El, N. Montcuquet, S. Martin- Lanneree, I. Dusanter-Fourt, V. Verkarre, J. J. Mention, G. Rahmi, H. Kiyono, E. A. Butz, N. Brousse, C. Cellier, N. Cerf- Bensussan and B. Meresse: IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J.Clin.Invest, 120(6), 2131-2143 (2010)
156. L. B. Gao, L. Rao, Y. Y. Wang, W. B. Liang, C. Li, H. Xue, B. Zhou, H. Sun, Y. Li, M. L. Lv, X. J. Du and L. Zhang: The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis, 30(2), 295-299 (2009)
157. D. Wagsater, K. Jatta, P. Ocaya, J. Dimberg and A. Sirsjo: Expression of IL-1beta, IL-1 receptor type I and IL-1 receptor antagonist in human aortic smooth muscle cells: effects of alltrans- retinoic acid. J.Vasc.Res., 43(4), 377-382 (2006) (Pubitemid 44167875)
158. S. Wildi, J. Kleeff, H. Maruyama, C. A. Maurer, M. W. Buchler and M. Korc: Overexpression of activin A in stage IV colorectal cancer. Gut, 49(3), 409-417 (2001) (Pubitemid 32802577)
159. Y. Takebayashi, K. Yamada, Y. Ohmoto, T. Sameshima, K. Miyadera, Y. Yamada, S. Akiyama and T. Aikou: The correlation of thymidine phosphorylase activity with the expression of interleukin 1 alpha, interferon alpha and interferon gamma in human colorectal carcinoma. Cancer Lett., 95(1-2), 57-62 (1995)
160. E. A. Choi, H. Lei, D. J. Maron, J. M. Wilson, J. Barsoum, D. L. Fraker, W. S. El-Deiry and F. R. Spitz: Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells. Cancer Res., 63(17), 5299-5307 (2003) (Pubitemid 37139844)
161. P. K. Turner, J. A. Houghton, I. Petak, D. M. Tillman, L. Douglas, L. Schwartzberg, C. A. Billups, J. C. Panetta and C. F. Stewart: Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer. Cancer Chemother.Pharmacol., 53(3), 253-260 (2004) (Pubitemid 38293724)
162. P. Stattin, R. Palmqvist, S. Soderberg, C. Biessy, B. Ardnor, G. Hallmans, R. Kaaks and T. Olsson: Plasma leptin and colorectal cancer risk: a prospective study in Northern Sweden. Oncol.Rep., 10(6), 2015-2021 (2003)
163. E. K. Toth, J. Kocsis, B. Madaras, A. Biro, Z. Pocsai, G. Fust, B. Blasko, I. Karadi, R. Adany and J. Laki: The 8.1 ancestral MHC haplotype is strongly associated with colorectal cancer risk. Int.J.Cancer, 121(8), 1744-1748 (2007) (Pubitemid 47417292)
164. B. Van, Jr., P. T. Moerkerk, A. J. Gerbers, A. P. De Bruine, J. W. Arends, H. R. Hoogenboom and S. E. Hufton: Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int.J.Cancer, 101(2), 118-127 (2002) (Pubitemid 34970903)
165. E. Tahara: Growth factors and oncogenes in human gastrointestinal carcinomas. J.Cancer Res.Clin.Oncol., 116(2), 121-131 (1990) (Pubitemid 20271913)
166. M. Mantur, O. Koper, J. Snarska, A. Sidorska and K. Kruszewska-Wnorowska: Evaluation of PDGF-AB and sPselectin concentrations in relation to platelet count in patients with colorectal cancer before and after surgical treatment. Pol.Arch.Med.Wewn., 118(6), 345-350 (2008) (Pubitemid 351960836)
167. S. Hsu, F. Huang and E. Friedman: Platelet-derived growth factor-B increases colon cancer cell growth in vivo by a paracrine effect. J.Cell Physiol, 165(2), 239-245 (1995)
168. D. Wagsater, M. Mumtaz, S. Lofgren, A. Hugander and J. Dimberg: Resistin in human colorectal cancer: increased expression independently of resistin promoter -420C > G genotype. Cancer Invest, 26(10), 1008-1014 (2008)
169. H. Ito, A. Yagita, M. Fujitsuka, Y. Atomi and I. Tatekawa: Tumor necrosis factor production and colon cancer. Jpn.J.Cancer Res., 87(11), 1160-1164 (1996) (Pubitemid 26420024)
170. S. Tanaka, K. Imanishi, M. Yoshihara, K. Haruma, K. Sumii, G. Kajiyama and S. Akamatsu: Immunoreactive transforming growth factor alpha is commonly present in colorectal neoplasia. Am.J.Pathol., 139(1), 123-129 (1991)
171. S. I. Berndt, W. Y. Huang, N. Chatterjee, M. Yeager, R. Welch, S. J. Chanock, J. L. Weissfeld, R. E. Schoen and R. B. Hayes: Transforming growth factor beta 1 (TGFB1) gene polymorphisms and risk of advanced colorectal adenoma. Carcinogenesis, 28(9), 1965-1970 (2007) (Pubitemid 47500610)
172. H. Nakagawa, S. Liyanarachchi, R. V. Davuluri, H. Auer, E. W. Martin, Jr., C. A. de la and W. L. Frankel: Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles. Oncogene, 23(44), 7366-7377 (2004) (Pubitemid 39382139)
173. A. Carrato, J. Gallego-Plazas and C. Guillen-Ponce: Anti- VEGF therapy: a new approach to colorectal cancer therapy. Expert.Rev.Anticancer Ther., 6(10), 1385-1396 (2006) (Pubitemid 44697164)
174. S. Munemitsu, I. Albert, B. Souza, B. Rubinfeld and P. Polakis: Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc.Natl.Acad.Sci.U.S.A, 92(7), 3046-3050 (1995)
175. M. Katoh: Frequent up-regulation of WNT2 in primary gastric cancer and colorectal cancer. Int.J.Oncol., 19(5), 1003-1007 (2001)
176. S. Kaiser, Y. K. Park, J. L. Franklin, R. B. Halberg, M. Yu, W. J. Jessen, J. Freudenberg, X. Chen, K. Haigis, A. G. Jegga, S. Kong, B. Sakthivel, H. Xu, T. Reichling, M. Azhar, G. P. Boivin, R. B. Roberts, A. C. Bissahoyo, F. Gonzales, G. C. Bloom, S. Eschrich, S. L. Carter, J. E. Aronow, J. Kleimeyer, M. Kleimeyer, V. Ramaswamy, S. H. Settle, B. Boone, S. Levy, J. M. Graff, T. Doetschman, J. Groden, W. F. Dove, D. W. Threadgill, T. J. Yeatman, R. J. Coffey, Jr. and B. J. Aronow: Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumour models and human colon cancer. Genome Biol., 8(7), R131 (2007)
177. J. Ying, H. Li, J. Yu, K. M. Ng, F. F. Poon, S. C. Wong, A. T. Chan, J. J. Sung and Q. Tao: WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. Clin.Cancer Res., 14(1), 55-61 (2008) (Pubitemid 351377978)
178. H. Kirikoshi, H. Sekihara and M. Katoh: WNT10A and WNT6, clustered in human chromosome 2q35 region with head-to-tail manner, are strongly coexpressed in SW480 cells. Biochem.Biophys.Res.Commun., 283(4), 798-805 (2001) (Pubitemid 32924650)
179. H. Kirikoshi and M. Katoh: Expression of WNT7A in human normal tissues and cancer, and regulation of WNT7A and WNT7B in human cancer. Int.J.Oncol., 21(4), 895-900 (2002)
180. T. Saitoh, T. Mine and M. Katoh: Up-regulation of WNT8B mRNA in human gastric cancer. Int.J.Oncol., 20(2), 343-348 (2002)
181. L. Ouko, T. R. Ziegler, L. H. Gu, L. M. Eisenberg and V. W. Yang: Wnt11 signaling promotes proliferation, transformation, and migration of IEC6 intestinal epithelial cells. J.Biol.Chem., 279(25), 26707-26715 (2004) (Pubitemid 38798828)